SMMT Summit Therapeutics Inc

$SMMT — Another major ivonescimab collaboration just dropped. Summit is working with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab alongside the TROP2 ADC Datroway across multiple tumor types. That’s on top of AstraZeneca’s recent $2B investment in Summit and the Nov. 14 FDA decision approaching. Ivonescimab is quickly becoming one of the more interesting oncology assets to follow.

$SMMT if you’re selling into this news, you’re picking up a penny in front of a steamroller. This is a Very Friendly $SMMT deal. If you think the company should be worth less today than it was a couple of days ago, I can’t help you….

$SMMT China created this drug and sold rights to Summit.....it is aready first line cancer drug in China and it will be 100% approved in the US....this is a no-brainer and Astrzeneca has shown their cards while playing poker....🤔 thank you for showing your hand I appreciate you 😉

$SMMT The amount if scrutiny the board of AZN had to take in due diligence of smmt to be able to approve an investment like that is insane. They are privvy to EVERYTHING Smmt has on and off the books. Having backing of AZN here within 45 days of FDA approval is genius and shows the confidence they have in it getting approved. No FDA approval will probably tank the stock to sub $10 which means they lose $1,000,000,000 in 45 days. Im sorry but people smarter than any of us looked at all the data and said Ivo has a great chance at being approved.

$SMMT 83% insider ownership and 4.6 institutions...🤔 if this is approved on Nov. 14 this short squeeze will make Gamestop look like an ant hill!!! Count me in 😝 (and upcoming conference 😍😍😍buy now and you will greatful😉)

$SMMT y’all need to chill so damn serious - by Nov 14 we print - know what you own turkeys.

$SMMT Since we solved financial pathway with the $2.X billion injection together with excellent effacicy... Whats left of the short thesis?

$SMMT what a jewel. Nothing but good news, hard work and strategic thinking from this biotech company. So happy to have found this.

$SMMT Wild to think a little nobody can buy shares of this company on the open market right now for a lower price than a sophisticated big pharmaceutical company just agreed to pay. For all the breathless talk of the market being rigged against the little guy, it’s somewhat surprising to me that opportunities like this are allowed to exist longer than a minute.

$SMMT Citi raised its Summit Therapeutics (SMMT) price target from $40 to $43 on September 29, 2026, following the announcement of AstraZeneca's $2 billion strategic investment.

$SMMT $NTLA I don't like to sound too cocky but I think soon we can start to celebrate the burying of the short thesis like we did with $SLS... 😎😎😎

$SMMT Bank of America acquired 864,983 Summit Therapeutics shares in the second quarter, valued at approximately $12.6 million and representing about 0.11% of the company.

$SMMT Lemme explain what this agreement means: No dilution when we get FDA approval and when ivo beats keytruda in OS. 50 by the end of year

$SMMT When shorts are heavily debt invested you will always see contradictional moves... It's part of a pattern... Thesis doesn't pan out as shorts theorised... Shorts are heavily debt invested... They don't cover their short no... They wait for quite periods and double down forcing leveraged and short term investors to sell in the hope that others will follow... Nothing new... Look at $SLS and $NTLA... All successful bio stocks with heavily debt invested shorts who pray for a miracle... 😎😎😎

$SMMT strong belief that this was manipulated very hard. I also understand that shorts have 6.6 days to cover. I know people wanna see huge gains but this is a slow simmer trapping shorts. Price over $18-20 is a shorts nightmare to cover. Anything above $24 they will never be able to cover quick enough to exit. Slow and steady the bulls will win the race.

$SMMT AstraZeneca's $2B buys ~12% of Summit at $18.36 and a guaranteed seat at any sale, with nothing that blocks one. If the board considers an outside bid, AZ gets notice within 2 business days and 10 days to counter, but no right of first refusal, no match and no veto. It's locked up a year, votes with the board, and converts to common on a buyout, so it sits alongside us, not ahead. AZ is positioning to be in the room for Ivo without paying a control premium, and nothing here scares off other bidders. I'm long SMMT.

$SMMT — Hard to overlook a $2B strategic investment from AstraZeneca while ivonescimab is approaching another major regulatory milestone.

$SMMT SQUEEZE. I wrote a few days ago that all we need is a catalyst like a major drug company to step in before the PDUFA date to set this off, ITS HAPPENED! Hold

$SMMT CASE CLOSED. 2 Billion is not a gamble, is not 'just' a vote of confidence...it's a confirmation. GAME OVER. Longs can relax and shorts now need to scramble...fast!!

$SMMT Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026